# Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe

- Source: PR Newswire M&A
- Published: 2026-11-04T18:45:00+00:00
- Category: Local
- Original: https://www.prnewswire.com/news-releases/citius-oncologys-positive-quality-of-life-data-for-lymphir-denileukin-diftitox-cxdl-in-relapsed-or-refractory-cutaneous-t-cell-lymphoma-presented-at-premier-global-cltg-congress-in-europe-302929643.html
- Canonical: https://groundlevelnews.com/story/citius-oncology-s-positive-quality-of-life-data-for-lymphir-denileukin-921e42/

Data featured in oral presentation at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) 2026 Annual Meeting in Berlin Patients who responded to LYMPHIR reported sustained improvement in skin-related quality of life measures...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._